Ovarian cancer is the most lethal of all the gynecologic malignancies, but little is known about the etiology, pathologic classification, or genetic progression of the disease. The most effective treatment of ovarian cancer would be to prevent it from developing in women. There is intense investigation exploring modalities such as screening and chemoprevention to prevent the development of ovarian cancer. To determine whether an approach is beneficial takes well-designed clinical trials, thousands of patients, and years of follow-up. More than any other malignancy, patients with ovarian cancer, with the support of their primary physicians, must be encouraged to participate in clinical trials. The natural history of the disease has changed with longer survival times associated with the use of surgery followed by chemotherapy as primary treatment. The recent literature has several reports of distant metastasis being detected in patients with ovarian cancer, a disease whose hallmark is local, not systemic, spread [1] . One study noted that over 20 years, in the experience of a single hospital, the incidence of brain metastasis in ovarian cancer had increased from 0.2% to 1.3% of cases. The investigators attributed this finding to the longer survival in patients with ovarian cancer treated with newer standard therapies [2] .
challenges in ovarian cancer: (1) prevention of relapse after optimal primary therapy and (2) management of recurrent and chemoresistant disease.
Therapeutic approaches to prevent ovarian cancer relapse
In general, ovarian cancers are sensitive to chemotherapy, and most patients can achieve a complete remission after standard treatment. One of the major clinical hurdles in the successful treatment of ovarian cancer is maintaining that first remission. Most patients diagnosed with more advanced stage disease go on to develop disease recurrence. Much interest has focused on the prevention of disease recurrence in ovarian cancer by manipulating initial treatment via different routes of administration of chemotherapy (ie, intraperitoneal [3] ), prolonged courses of initial chemotherapy [4, 5] , or the use of neoadjuvant chemotherapy before optimal initial debulking surgery [6] . Future strategies might entail the use of biologic therapies after standard chemotherapeutic strategies as consolidation or maintenance following primary treatment. A combination of cytotoxic agents with molecularly targeted approaches may allow the eradication of the minimal residual disease responsible for ovarian cancer relapse. Several novel therapies are being tested in human clinical trials. Examples of promising agents include vaccines directed toward ovarian cancer antigens, agents that inhibit invasion or metastasis, drugs that inhibit prostaglandin synthesis, and approaches that interfere with signal transduction pathways within the ovarian cancer cell responsible for malignant growth.
Vaccines targeting ovarian cancer are being tested in the clinic for potential efficacy in preventing disease relapse. As more ovarian cancer antigens are becoming defined [7] , the clinical application of ovarian cancer vaccines is being focused on patients with minimal disease. In the past, vaccines targeting ovarian cancer often were administered in the presence of bulky disease and had limited therapeutic success. Extrapolating from the application of active immunization in infectious diseases, vaccines such as those targeting chickenpox or influenza are given in the absence of infection and have only limited efficacy if administered after exposure to the pathogen. The goal of vaccination against ovarian cancer would be to elicit significant immunologic memory capable of rapidly expanding an antigen-specific T-cell population in the presence of low levels of antigen encountered during relapse. Vaccination against ovarian cancer likely would be effective only when disease is either absent or below the limit of detection. The two primary reasons for vaccinating in the absence of bulky disease are (1) patients with existing disease are often immunosuppressed, and (2) the response to repeated vaccination in the absence of disease is limited and reaches a plateau level that is insufficient to eradicate existing malignancy before death occurs. Studies have shown that active immunization of patients with ovarian cancer in remission or with minimal disease results in a significant increase in HER-Z/neu specific cytotoxic T-cell precursor frequency [8] . Even autologous ovarian tumor cells derived from the primary surgery can be used as a ''multiantigen'' vaccine in the adjuvant setting [9] . Now that the feasibility of immunizing patients with ovarian cancer against their tumor has been shown, clinical studies can move forward attempting to determine whether immunity against ovarian cancer can prevent relapse.
An alternative strategy is one that would attempt to limit the malignant potential of residual disease by preventing the development of revascularization of the residual tumor (eg, inhibiting angiogenesis) or preventing the outgrowth of clones that had an invasive growth advantage (eg, inhibiting the function of matrix metalloproteinases). Several studies have shown factors that mediate angiogenesis, the development of new blood vessels from the existing vasculature, which are elevated in patients with ovarian cancer and, in some cases, correlate with the clinical progression of the disease [10] . One investigation evaluated the role of preoperative serum vascular endothelial growth factor (VEGF) levels in predicting the presence of ovarian cancer [11] . VEGF is a naturally occurring growth factor that can induce or promote angiogenesis by stimulating the growth and migration of endothelial cells. In addition, the presence of VEGF greatly enhances vascular permeability. Investigators assessed the levels of VEGF in 101 women with invasive epithelial ovarian cancers, 16 women with low malignant potential ovarian tumors, and 34 women with benign ovarian tumors. VEGF levels were more likely to be elevated in patients with invasive cancers, particularly patients with ascites, than in patients with more benign disease [11] . In animal models of ovarian cancer, antiangiogenic proteins delivered intraperitoneally via adenoviral vectors resulted in a marked decrease of ascites formation and tumor growth [12] . After administration of agents such as angiostatin, endostatin, and platelet factor 4, alone or in combination, tumor growth and vascularity decreased, resulting in prolongation of survival in treated animals.
Although the role of increased angiogenesis in mediating the malignant potential of ovarian cancer may not be as well defined as in other cancers, such as breast cancer [10] , clinical studies evaluating antiangiogenic approaches alone or combination with chemotherapy in ovarian cancer are under way. One clinical trial evaluated the safety and toxicity of combining an antiangiogenesis and antiinvasion agent, carboxyamido-triazole, with the cytotoxic agent paclitaxel. A total of 39 patients were treated on a dose escalation study. Although the study showed that paclitaxel caused an increase in the circulating carboxyamido-triazole level in a dose-dependent fashion, no additive toxicity was observed. Clinically, three partial responses and two minor responses were observed in this heavily pretreated population [13] .
Anti-invasion agents also may play a role in limiting the migration of ovarian cancer throughout the peritoneum. Matrix metalloproteinases such as MMP-2 and MMP-9 have been shown to be up-regulated in advanced stage ovarian cancer [14] . Matrix metalloproteinases are key enzymes responsible for the breakdown of the extracellular matrix. The extracellular matrix holds the cell together and plays a crucial role in the growth, differentiation, and stability of the cell. The extracellular matrix is a major physical barrier to cellular migration. Breakdown of the extracellular matrix by matrix metalloproteinases enhances the metastatic potential and invasive properties of ovarian cancer cells. Studies have shown that increased levels of MMP-2 and MMP-9 are associated with the progression of ovarian cancer from limited to metastatic disease [15] . Investigators evaluated the levels of matrix metalloproteinases in tissue extracts of benign ovarian tumors, tumors of low malignant potential, and invasive ovarian cancers including metastatic lesions. MMP-2 was detected in cancers and corresponding metastasis but never in benign tumors. The highest levels of the proteolytic factors were found in omental metastasis. An additional study by the same team of investigators showed that expression of the latent form of MMP-9 was an independent predictor of poor survival in patients with advanced ovarian cancer along with residual disease after optimal therapy [16] .
Several matrix metalloproteinase inhibitors have been developed and tested for antitumor effect in a variety of clinical trials. These agents have shown little clinical activity due to a variety of reasons-poor bioavailability of early formulations, phase II study designs assessing cytotoxic end points when the drugs mediated a cytostatic effect, and lack of biologic surrogates to monitor the effect of different agents [17] . An additional explanation for the disappointing clinical outcome data is that successful murine models of matrix metalloproteinase inhibitors generally focused treatment on minimal or early stage disease and continued treatment for extended periods. Human clinical trials generally studied the effects of the agents in patients with advanced stage disease [17] . Considering the importance of matrix metalloproteinases in mediating the metastatic potential of ovarian cancer, one can envision trials in patients who have been treated to maximal response using the agents in a maintenance approach to prevent the outgrowth of cells that have upregulated these invasion-related enzymes.
In recent years, the importance of the cyclooxygenase (COX) system in oncogenesis has been underscored in many malignancies, most notably colon cancer. The COX enzyme system is part of the prostaglandin synthetase complex of enzymes and plays a role in the generation of prostaglandins within a cell. A distinct isoenzyme in this system, COX-2, has been found to be up-regulated in a variety of common malignancies. COX-2 is involved in many inflammatory pathways. In in vitro and in vivo models of cancer, induction of COX-2 is associated with increased cell growth, inhibition of apoptosis, and enhanced cell motility and adhesion [18] . Expression of COX-2 has been studied extensively in ovarian cancer, and its role as a prognostic indicator is not yet defined [19] . One investigation of more than 100 ovarian tumors showed that COX-2 was expressed exclusively in ovarian cancer-invasive cancers and tumors of low malignant potential-compared with benign tumors [20] . In a multivariate analysis, expression of COX-2 was an independent prognostic factor for poor survival. In a separate study, COX-2 expression was associated with patients most likely to be resistant to chemotherapy [21] . Investigators have begun to evaluate the effects of the inhibition of COX-2 in ovarian cancer. One report showed that a variety of nonsteroidal anti-inflammatory drugs, including aspirin and COX-2 inhibitors, could reduce significantly the rate of proliferation and mitotic activity of human ovarian cancer cell lines in culture [22] . Several clinical agents are available that inhibit the expression of COX-2, and these agents are being studied as antineoplastics in a variety of cancers [23] . The COX pathway is important in pathogenesis of ovarian cancer, and COX-2 inhibitors should be tested for clinical utility in the treatment and prevention of primary ovarian cancer and ovarian cancer relapse.
A final novel therapeutic strategy in the treatment of ovarian cancer would be to ''turn off'' the signaling pathways involved in unregulated cell growth. The clinical use of kinase inhibitors has been an area of intense investigation. In particular, several studies have evaluated the therapeutic efficacy of ZD1839 (Iressa), which is an orally selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Theoretically, ZD1839 would block the signal transduction pathways involved in cell proliferation. Most ovarian cancers ( > 70%) express high levels of EGFR. Experiments using EGFR antisense in the treatment of ovarian cancer cells in vitro showed that knocking out receptor function resulted in reversion of the invasive phenotype of these cells [24] . Other investigators showed that incubation of human ovarian cancer cell lines with ZD1839 inhibited the growth of cells in vitro [25] . Preclinical studies in a variety of models have suggested that tyrosine kinase inhibitors, such as ZD1839, may have additive to synergistic effects when added to other standard therapies, such as radiation or chemotherapy [26] . Although not formally tested in clinical trials of ovarian cancer, ZD1839, similar to the matrix metalloproteinase inhibitors, has not had much therapeutic success in the treatment of advanced stage solid tumors. Clinical trials in minimal residual disease states may be more therapeutically effective. In addition, studies in animal models have suggested that combination noncytotoxic therapies may be much more effective than a single agent used alone. Investigators have treated cancerbearing nude mice with a combination of inhibitors of protein kinase A, ZD1839, and a taxane [27] . The combination therapy had a marked antitumor effect, with half of the mice being rendered disease-free after treatment.
Recurrence of ovarian cancer after optimal primary therapy is a major clinical problem in the treatment of this disease. Novel approaches aimed at eradicating minimal residual disease that exists and is clinically undetectable after treatment and that eventually will recur are needed. Patients with stage III and IV ovarian cancer who have been treated to the point where they have no evidence of disease have few treatment options other than to be observed for relapse. This is the ideal patient population for testing biologic approaches to tumor control. Preclinical studies in animal models and with human ovarian cancer cells and biopsy specimens have suggested that many molecularly targeted approaches, useful in the treatment of other solid tumors, may be effective in interfering with ovarian cancer invasion and metastatic progression.
Strategies for long-term management of recurrent disease
Most patients with advanced ovarian cancer have a disease recurrence despite successful primary treatment. The development of chemoresistant disease is a hallmark of recurrent ovarian cancer. Several novel therapeutic options for the management of recurrent disease have focused on mediating chemoresistance. Strategies to overcome drug resistance include the use of high-dose chemotherapy in the setting of stem cell rescue and replacement of genes involved in mediating drug resistance via gene therapy.
Autologous stem cell transplantation has been studied as a treatment modality in relapsed progressive ovarian cancer since the 1990s. A summary of results of more than 50 centers that have performed stem cell transplants for ovarian cancer has been reported [28] . Review of the clinical characteristics of the more than 400 women who received transplants for ovarian cancer between 1989 and 1996 showed most of the patients had received previous extensive chemotherapy, almost half had platinum-resistant tumors, and more than one third had tumors at the time of transplant of at least 1 cm. The 2-year progression-free survival was only 12%, and the 2-year overall survival (OS) was 35%. Subsets of patients who achieved a greater benefit could be shown, however (eg, patients with a high Karnofsky performance score [OS 22%] and patients with non -clear cell, platinum-sensitive tumors [OS 55%]) [28] .
More recent studies have attempted to improve results by using dose intensive therapy as initial treatment. Investigators treated 15 patients with newly diagnosed stage IIIC and IV ovarian cancer with intensive chemotherapy consisting of highdose cyclophosphamide, paclitaxel, and carboplatin along with stem cell support [29] . Before chemotherapy, the patients underwent surgical debulking, which was optimal in eight patients and suboptimal in seven. A second-look surgery was performed after treatment in 14 patients; all had macroscopic complete response, and 10 had microscopic complete response. At a median follow-up of 48 months, three patients remained disease-free and nine were alive with recurrent disease [29] . A more recent strategy to optimize a survival benefit is to use marrow ablative chemotherapy as an immunotherapy to initiate a graft-versus-tumor effect in the setting of allogeneic transplant. As previously discussed, vaccination against ovarian cancer can increase the number of immune T cells capable of recognizing and responding to the tumor-specific antigens. Repeated vaccination further increases the number of immune effector cells, but eventually a plateau of responsiveness is reached, and repeated immunizations do not change this value appreciably [30] .
Another therapeutic intervention that may increase greatly the tumor-specific T-cell precursor frequency is allogeneic hematopoietic stem cell transplantation (alloHSCT). AlloHSCT has been effective in treating hematopoietic malignancy; a significant part of the curative potential of alloHSCT is due to reactivity of donor immune cells against host or tumor cell antigens, called the graft-versusleukemia or graft-versus-tumor effect [31, 32] . The most compelling evidence for a cell-mediated, graft-versus-tumor effect comes from observations that the infusion of allogeneic lymphocytes, or donor lymphocyte infusion, results in the remission of leukemic cells without any further cytotoxic therapy in patients who experienced relapse of disease after traditional alloHSCT [33, 34] . The effectiveness of donor lymphocyte infusion in inducing the remission of recurrent malignancy has been shown for almost all hematologic malignancies, although its efficacy varies across tumor subtypes [35] . More recently, investigators have begun to use this strategy in the treatment of solid tumors [36] including relapsed progressive ovarian cancer [37] . In an initial study, five patients with relapsed and chemoresistant ovarian cancer underwent alloHSCT from HLA identical siblings. Two patients received additional donor lymphocyte infusions after transplant. Four of the patients developed acute or chronic graft-versus-host disease associated with tumor regression of at least 50% as assessed by CT scan or CA-125 levels [37] . Although initial results are provocative, further study is needed to determine whether this therapeutic strategy would be of benefit in patients with relapsed ovarian cancer.
An approach to overcome chemoresistance directly would be to manipulate the genes involved in mediating chemoresistance in vivo. The p53 tumor-suppressor gene is important in cell cycle regulation and mediating apoptosis. Mutations in the p53 gene, which occur in more than 50% of ovarian cancers, inactivate the normal function of the protein and result in ''immortalization'' of the ovarian cancer cell. Investigators have begun to explore the role p53 mutations may play in the development of drug-resistant disease. In one study, 178 ovarian cancers were evaluated for abnormalities in p53, and 56% of patient tumors were found to harbor mutations. Resistance to cisplatin or carboplatin chemotherapy was significantly more frequent in patients with abnormal p53 [38] . Translating this observation to the clinic, a study evaluated the coadministration of an adenoviral vector encoding recombinant human wild-type p53 delivered intraperitoneally with platinum-based chemotherapy in patients with recurrent ovarian cancer in an attempt to reverse drug resistance [39] . Responses, defined as greater than a 50% decrease in serum CA-125 levels from baseline, were achieved in 8 of 16 women who completed three cycles of the multidose regimen (p53 gene therapy alone for cycle 1, then given with chemotherapy for cycles 2 and 3).
While approaches targeting mutant p53 are advancing in the clinic, several other genes associated with the development of chemoresistance are being evaluated at the preclinical level. One strategy is to target directly the multidrug resistance gene (MDR). Investigators have shown that a single-chain variable fragment from a monoclonal antibody that is specific for the intracellular domain of MDR could reverse partially doxorubicin (Adriamycin) resistance in cell culture in vitro [40] . Other novel preclinical strategies for reversing drug resistance include inducing apoptosis via activation of the Fas ligand pathway [41] . Recombinant CD40 ligand, a member of the tumor necrosis receptor family, has been shown to have an antitumor effect on human ovarian cancers transplanted into SCID mice. When CD40 ligand was administered with chemotherapy using cisplatin, the antitumor effect was additive over CD40 ligand alone and when given with a suboptimal dose of cisplatin could mediate an antitumor effect equivalent to a full dose [41] . More recent work shows that it may be possible to ameliorate ovarian cancer drug resistance in vivo. These promising early clinical and preclinical studies need to be translated rapidly to the bedside for evaluation in patients with relapsed disease.
Monoclonal antibody therapy long has been studied as potential cancer therapy, and at last significant antitumor effects are being seen with agents such as trastuzumab in breast cancer and rituximab in lymphoma. Several clinical trials exploring a variety of different antibody therapies are being evaluated in patients with ovarian cancer. One clinical trial examined the use of a bispecific antibody, HEA124xOKT3, in patients with relapsed ovarian cancer. HEA124 is directed against the surface antigen, Ep-CAM, which is overexpressed on most epithelial cancer cells, and OKT3 targets the T lymphocyte via CD3 [42] . Ten ovarian cancer patients with malignant ascites resistant to chemotherapy were treated with weekly intraperitoneal injections of HEA124xOKT3. Eight patients experienced a complete resolution of ascites, whereas two patients had a partial reduction in ascites production. A decrease or stabilization in the CA-125 level was seen in eight patients.
Antibodies targeting CA-125 also have been used for the treatment of advanced stage ovarian cancer. A murine monoclonal antibody targeting CA-125, MAb-B43.13, previously administered as an imaging agent to monitor disease recurrence in patients with ovarian cancer, was observed to impart a survival benefit in these patients. Further evaluation of the mechanisms of the response indicated that patients treated with the antibody developed B-cell and T-cell immunity specific for CA-125 [43] . Mucin-specific antibodies also have been assessed in human clinical trials. One study evaluated the antitumor effect of a mucin-specific antibody, CMB-401, linked to the cytotoxic antibiotic calicheamicin [44] . A total of 34 patients with progressive ovarian cancer received up to four cycles of therapy. Although the trial was a dose escalation study and the maximum tolerated dose was reached at the highest dose, four patients had greater than a 50% reduction in CA-125, and three patients showed radiographic responses. Clinical responses to antibody therapy potentially can be optimized by linking the antibody to a cytotoxic agent as described or by using the antibody as a carrier to deliver targeted radiotherapy directly to the sites of tumor [45] . It is hoped that future studies of newer strategies to optimize monoclonal antibody therapy will result in some durable clinical responses in patients with relapsed and advanced stage ovarian cancer.
Approaches to advanced stage ovarian cancer should focus on the control of the disease. Combination therapies alternating cytoreductive chemotherapy with one or more biologically based approaches may extend the time until the development of complete drug resistance, offer the patient breaks from toxic treatments while maintaining stabilization of the disease, and prevent rapid metastasis. While clinicians struggle to find methods to prevent and cure ovarian cancer, using novel therapies may extend life and quality of life by working to turn relapsed ovarian cancer into a ''chronic disease.''
Summary
As investigators at the bench define the oncogenic pathways involved in ovarian cancer growth and invasion, clinical scientists will develop therapies to target these important pathways. The approach to the treatment of ovarian cancer will change to focus on strategies designed to eliminate minimal residual disease after primary therapy and in this way cure the disease. Concepts of consolidation after standard adjuvant chemotherapy and maintenance regimens will start to be evaluated for clinical efficacy. In addition, the focus on recurrent disease may change from repeated cytotoxic approaches to regimens chosen to prevent invasion or the development of drug resistance, changing the approach to ovarian cancer recurrence to a treatment plan of managing a chronic, but not imminently terminal, disease.
